Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting

October 28, 2019

Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures

ePoster to be presented at ACR Annual Meeting on Tuesday, November 12

EVANSTON, Ill., Oct. 28, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with fibromyalgia have been selected for a late-breaking poster presentation at the American College of Rheumatology Annual Meeting. The study was conducted in collaboration with the Chronic Pain and Fatigue Research Center at the University of Michigan Medical School and the Women’s Health Research Program at University of Cincinnati College of Medicine.

“The opportunity to showcase these clinical data in a late-breaking presentation demonstrates their scientific importance in a field in dire need of new therapeutic options,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. “We and our collaborators at the University of Michigan and the University of Cincinnati are very pleased with the clinical data yielded from this study. These data demonstrate that NYX-2925 is affecting biomarkers known to be associated with centralized pain processing, and that the activity of NYX-2925 resulted in improvements on pain scores and other patient-reported symptoms. Taken together, the imaging data and the clinical outcomes from this study are highly supportive of the continued development of NYX-2925 in chronic centralized pain conditions.”

Full press release here.